Adiponectin in chronic kidney disease: Dr Jekyll and Mr Hyde

Kidney International

Volumn 75, Issue 1, 2009, Pages 120-121

  Carrero, Juan J ^a   Brodin, Lovisa ^a   Lindholm, Bengt ^a   Stenvinkel, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; FAT;

BLOOD VESSEL INJURY; CHRONIC KIDNEY DISEASE; ENERGY EXPENDITURE; HEART FAILURE; HUMAN; LETTER; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 58049199369     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.541     Document Type: Letter

References (6)

1. Costacou T, Orchard TJ. Adiponectin: good, bad, or just plain ugly?. Kidney Int 2008; 74: 549-551.
2. Yang WS, Lee WJ, Funahashi T et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
3. Kistorp C, Faber J, Galatius S et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005; 112: 1756-1762.
4. Matsumoto M, Ishikawa S, Kajii E. Adiponectin and noncardiovascular death: a nested case-control study. Metabolism 2008; 57: 811-818.
5. Qi Y, Takahashi N, Hileman SM et al. Adiponectin acts in the brain to decrease body weight. Nat Med 2004; 10: 524-529.
6. Barazzoni R, Stulle M, Panzetta G et al. Plasma high- but not low-molecular weight adiponectin is positively associated with resting energy expenditure in male non-diabetic hemodialysis patients (Abstract). J Ren Nutr 2008; 18: S36.